Abstract
Urinary excretion of the unchanged drug and perphenazine-sulfoxide was measured in a group of patients receiving at first oral perphenazine (24 mg dd) and after some weeks perphenazine-enanthate, a long-acting injectable preparation (100 mg per 14 days). A significant decrease in the absolute quantities of unchanged perphenazine and of the sulfoxide was observed. There was no constant ratio between the quantities excreted. A relative increase in the excretion, expressed in percentages of the administrated dose, was demonstrated.
Similar content being viewed by others
References
Ebert, A. G., Hess, S. M.: The distribution and metabolism of perphenazine-enanthate. J. Pharmacol. exp. Ther. 148, 412–421 (1965).
Hollister, L. E., Curry, S. H., Derr, J. E., Kanter, S. L.: Studies of delayed-action medication. V. Plasma levels and urinary excretion of four different dosage forms of chlorpromazine. Clin. Pharmacol. Ther. 11, 49–59 (1970).
Huang, C. L., Kurland, A. A.: Perphenazine (trilafon) metabolism in psychotic patients. Arch. gen. Psychiat. 10, 639–646 (1964).
Kanig, K., Breyer, U.: Urinary metabolites of perazine in psychiatric patients. Psychopharmacologia (Berl.) 14, 211–220 (1969).
Ragland, J. B., Kinross-Wright, V. J., Ragland, R. S.: Determination of phenothiazines in biological samples. Analyt. Biochem. 12, 60–69 (1965).
Sanders, G. T. B.: Psychofarmaca in rattehersenen (Psychopharmacological agents in rat brain). Thesis, Leiden 1969.
Tompsett, S. L.: The detection and determination of phenothiazine drugs in urine. Acta pharmacol. (Kbh.) 26, 303–315 (1968).
Author information
Authors and Affiliations
Additional information
The author wishes to express his gratitude to W. De Waard, psychiatrist, who supervised the clinical trial in this Hospital, for his cooperation and Miss M. Potman, Mr. R. Van Elk and Mr. A. Van de Weerthof for their technical assistance.
Rights and permissions
About this article
Cite this article
van Kempen, G.M.J. Urinary excretion of perphenazine and its sulfoxide during administration in oral and long-acting injectable form. Psychopharmacologia 21, 283–286 (1971). https://doi.org/10.1007/BF00403866
Received:
Issue Date:
DOI: https://doi.org/10.1007/BF00403866